FINNENCE ▪ THE WIRE FILE
THE WIRE · № 83884
News■ Unclear/unknown
Perceptive Discovery Launches Astatine-211 Study Capabilities in the US and UK
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Expanding radiopharmaceutical study capacity supports niche drug development infrastructure, not near-term revenue.
Radiopharma infrastructure expands modestly
CATALYST TO WATCH
Client study adoption
MAIN RISK
Niche demand may stay small
FULL DISPATCH
Perceptive Discovery becomes the first US provider able to support At-211 studies, expanding access to specialized radiopharmaceutical development infrastructure through its collaboration with Atley Solutions BOSTON, Oct. 16, 2026 /PRNewswire/ -- Perceptive Discovery today announced the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDSPDR Biotech ETF · XBI
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
The chairman bought 29,250 shares in CytoMed Therapeutics (NASDAQ: GDTC) and reported his stake.2026-10-16 10:06 UTC
The chairman bought 29,250 shares in CytoMed Therapeutics (NASDAQ: GDTC) and reported his stake.2026-10-16 10:06 UTC
→CORRELATIONshares Healthcare
Rush-Endeavor merger faces a test over scale and insurer leverage2026-10-16 10:15 UTC
Rush-Endeavor merger faces a test over scale and insurer leverage2026-10-16 10:15 UTC
→CORRELATIONshares Healthcare, XBI
City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field2026-10-16 10:17 UTC
City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field2026-10-16 10:17 UTC
→CORRELATIONshares Healthcare
Extrawell Pharmaceutical Abandons Negotiations For Possible Sale Of Convertible Bonds2026-10-16 10:19 UTC
Extrawell Pharmaceutical Abandons Negotiations For Possible Sale Of Convertible Bonds2026-10-16 10:19 UTC
→CORRELATIONshares Healthcare, XBI
Iambic Therapeutics raises USD 150m in Nasdaq IPO2026-10-16 10:24 UTC
Iambic Therapeutics raises USD 150m in Nasdaq IPO2026-10-16 10:24 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.